Early or late guided missile in the treatment of Crohn's disease?

Digestive and Liver Disease

Volumn 37, Issue 12, 2005, Pages 973-979

  Caprilli, R ^a   Angelucci, E ^a   Cocco, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biological agents; Crohn's disease (CD); Infliximab

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MERCAPTOPURINE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; GASTROINTESTINAL AGENT; INTERLEUKIN 12; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG RESPONSE; DRUG SELECTIVITY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HUMAN; IMMUNE DEFICIENCY; LICENSING; LYMPHOMA; PATHOGENESIS; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; SHORT SURVEY; TUBERCULOSIS; BIOLOGICAL THERAPY; DRUG ANTAGONISM; METHODOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTERLEUKIN-12; RECEPTORS, INTERLEUKIN-6;

EID: 33644877046     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.07.003     Document Type: Short Survey

References (52)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
2. Farmer R.G., Whelan G., and Fazio V.W. Long-term follow-up of patients with Crohn's disease. Gastroenterology 88 (1985) 1815-1825
3. Michelassi F., Balestracci T., Chappell R., and Block G.E. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 214 (1991) 230-238
4. Carter M.J., Lobo A.J., Travis S.P., IBD Section, and British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 Suppl. 5 (2004) V1-V16
5. Targan S.R., Hanauer S.B., Van Deventer S., Mayer L., Present D., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 tumor necrosis factor α for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
6. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
7. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116 (1999) 1029-1034
8. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
9. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
10. Lichtenstein G.R., Yan S., Bala M., Blank M., and Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
11. Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha 4 integrin in active Crohn's disease. Gastroenterology 121 (2001) 268-274
12. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32
13. Ito H., Takazoe M., Fukuda Y., Hibi T., Kusugami K., Andoh A., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004) 989-996
14. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
15. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., and Belaike J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
16. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. The natural history of corticosteroid therapy for IBD: a population based study. Gastroenterology 121 (2001) 255-260
17. Candy S., Wright J., Gerber M., Adams G., Gerig M., and Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 (1995) 674-678
18. Papi C., Festa V., Fagnani C., Stazi A., Antonelli G., Moretti A., et al. Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis 37 (2005) 247-253
19. Sandborn W.J., and Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 122 (2002) 1592-1608
20. MacDonald T.T., Monteleone G., and Pender S.L. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51 (2000) 2-9
21. Papadakis K.A., and Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51 (2000) 289-298
22. Van Deventer S.J. Tumour necrosis factor and Crohn's disease. Gut 40 (1997) 443-448
23. Neurath M.F., Becker C., and Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 43 (1998) 856-860
24. Schreiber S. Interleukin-10 in the intestine. Gut 41 (1997) 274-275
25. Kontoyiannis D., Pasparakis M., Pizarro P.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
26. Kosiewicz M.M., Nast C.C., Krishnan A., Rivera-Nieves J., Moskaluk C.A., Matsumoto S., et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 107 (2001) 695-702
27. Kontoyiannis D., Boulougouris G., Manoloukos M., Armaka M., Apostolaki M., Pizarro P.T., et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 196 16 (2002) 1563-1574
28. Simpson S.J., Shah S., Comiskey M., de Jong Y.P., Wang B., Mizoguchi E., et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 187 (1998) 1225-1234
29. Ten Hove T., Van Montfrans C., Peppelenbosch M.P., and Van Deventer S. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
30. D'Haens G., Geboes K., Ponette E., Penninck X., and Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112 (1997) 1475-1481
31. D'Haens G., Geboes K., and Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo) colitis with azathioprine. Gastrointest Endosc 50 (1999) 667-671
32. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibody in Crohn's disease: a European multicenter trial. Gastroenterology 116 (1999) 1029-1034
33. Lionetti P., Bronzini C., Salvestrini C., Bascietto C., Berni Canani R., De Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 18 (2003) 425-431
34. Borrelli O., Bascietto C., Viola F., Bueno de Mesquita M., Barbato M., Mancini V., et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 36 (2004) 342-347
35. Grand R.J. Inverting the therapeutic triangle. J Pediatr Gastroenterol Nutr 40 Suppl. 1 (2005) S50-S52
36. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
37. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
38. Breedveld F.C., Emery P., Keystone E., Patel K., Furst D.E., Kalden J.R., et al. Infliximab in early rheumatoid arthritis. Ann Rheum Dis 63 (2004) 149-155
39. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3423-3443
40. Markowitz J., Grancher K., Kohn N., Lesser M., and Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
41. Hommes D., Baert F., Van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): top-down versus step-up strategies. Gastroenterology 128 Suppl. 2 (2005) A577
42. Munkholm P., Langhols E., Davidsen M., and Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30 (1995) 699-706
43. Silverstein M.D., Loftus E.V., Sandborn W.J., Tremaine W.J., Feagan B.G., Nietert P.J., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 117 (1999) 49-57
44. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
45. Ljung T., Karlen P., Schmidt D., Helstrom P.M., Lapidus A., Ianczewska I., et al. Infliximab in inflammatory bowel diseases: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
46. Sandborn W.J., and Loftus E.V. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel diseases. Gut 53 (2004) 780-782
47. Keane J., Gershon S., Wise R.P., Mirabile-levens E., Kasznica J., Schwieterman W.D., et al. Tubercolosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 345 (2001) 1098-1104
48. Myers A., Clark J., and Foster H. Tubercolosis and treatment with infliximab. N Engl J Med 346 (2002) 623-626
49. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46 (2002) 2565-2570
50. Remicade (infliximab) for IV injection. Package Insert. Centocor, Malverne, PA, USA; 2003.
51. Biancone L., Kohn A., Colombo E., Sostegni R., Rizzello F., Viscido A., et al. Development of neoplasia in Crohn's disease patients treated with infliximab: a case-control study in an Italian population. Gastroenterology 128 Suppl. 2 (2005) P-126 #778
52. Data from Centocor, on file.